Anti-Leukemic Effect of Wharton Jelly Derived Mesenchymal Stem Cells in Vitro


Creative Commons License

Süleymanoğlu M., Erol A., Abatay Sel F., Özdemir İ. A., Oğuz F., Kuruca D. S., ...Daha Fazla

VIII. International Congress of Molecular Medicine, 9 - 12 Kasım 2021, ss.1

  • Yayın Türü: Bildiri / Özet Bildiri
  • Sayfa Sayıları: ss.1
  • İstanbul Üniversitesi Adresli: Evet

Özet

Besides that mesenchymal stem cells (MSCs) have the capacity for self-renewal and multipotency, their possible anti-cancer effects making them a primary candidate for cell-based therapy. The purpose of this study was to evaluate in vitro anti leukemic effect of Wharton Jelly derived MSC (WJ-MSC) on the K562 and HL-60 cells.

In this study, WJ-MSCs were isolated from an umbilical cord. According to standard culture conditions, the cells incubated and characterized by flow cytometry. For experiments, WJ-MSC and leukemic cells were incubated in the direct co-culture at a ratio of 1:5 (leukemia cells:WJ-MSC). We analyzed the apoptotic effect of WJ-MSCs on K562 and HL-60 cells with AnnexinV/PI assay by flow cytometry. After the direct co-culture of WJ-MSCs on leukemic cell lines, we observed anti-leukemic effect by inducing apoptosis. We had 2 groups of determination apoptosis with and without WJ-MSCs. In untreated and treated experimental groups for K562, we found increasing of apoptosis respectively (from 3,7% to 11,5%). For HL-60 cells, when compared between two groups apoptosis percentages were 15% (untreated) and 56% (treated). The increasing ratio of apoptotic cells was (approximately 3 folds) similar both for HL-60 and K562 cells.

MSCs are known to inhibit tumor growth of hematopoitic and non-hematopoietic origin in vitro. Treatment with WJ-MSC led to potentproliferation inhibition of HL-60 and K562 cells with inducing apoptosis. Our results provide new insight into how WJ-MSCs inhibit tumor growth in vitro. In the future, WJ-MSCs may be an option for their clinical use for the inhibition of cancer cells.